Disease · MONDO_0100431

migraine without aura

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. migraine without aura. Diseases, record MONDO_0100431. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100431

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: migraine without aura; Open Targets
Open Targets ID: MONDO_0100431; Open Targets
Other names: common migraine; Open Targets
Disease Ontology: DOID:12783; Disease Ontology
MeSH: D020326; MeSH
NCI Thesaurus: C117004; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 15 drugs, from ClinicalTrials.gov; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SUMATRIPTAN	CHEMBL128	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROCHLORPERAZINE	CHEMBL728	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUNARIZINE HYDROCHLORIDE	CHEMBL552659	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CILOSTAZOL	CHEMBL799	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
LEVCROMAKALIM	CHEMBL100	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
AMITRIPTYLINE	CHEMBL629	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
AMLODIPINE	CHEMBL1491	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets62

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
CA2	Carbonic anhydrase 2	1	Carbonic anhydrase II inhibitor	Unknown	https://conductscience.org/library/genes/760	Drugs and targets
CA4	Carbonic anhydrase 4	1	Carbonic anhydrase IV inhibitor	Unknown	https://conductscience.org/library/genes/762	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/779	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/1813	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets

1 to 10 of 62

See all 62 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00387881	TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)	Phase 3	679	2009-07-10	Migraine, Without Aura	NAPROXEN, SUMATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT00258609	Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study	Phase 3	128		Migraine Without Aura Prophylaxis	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT03461874	ACT Therapy for HF Migraine	Not applicable	64		Migraine Without Aura	AMITRIPTYLINE, PROPRANOLOL, TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT07068815	Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura	Phase 1	60		Migraine Without Aura	FLUNARIZINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00274170	Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache	Phase 1/2	56		Migraine Headache	OCTREOTIDE, PROCHLORPERAZINE	Its record names the disease	ClinicalTrials.gov
NCT04853797	Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)	Not applicable	37		Headache, Migraine Without Aura	IVABRADINE, LEVCROMAKALIM	Its record names the disease	ClinicalTrials.gov
NCT02485340	The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache	Not applicable	30		Migraine	SUMATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT02486276	The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache	Not applicable	30		Migraine	CILOSTAZOL, SUMATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT03422796	The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache	Not applicable	30		Migraine	CILOSTAZOL, SUMATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT03542357	The Effect of Sumatriptan and Placebo on CGRP Induced Headache	Not applicable	30		Migraine	SUMATRIPTAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sumatriptan/Naproxen vs Placebo: serious adverse events	0 of 254	0 of 246	500	NCT00387881	Trial comparisons
Sumatriptan/Naproxen vs Placebo: Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment	61 of 222	101 of 221	443	NCT00387881	Trial comparisons
Sumatriptan/Naproxen vs Placebo: Sustained Headache Relief 2-24 Hours After Treatment	110 of 222	77 of 221	443	NCT00387881	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41930571	DERIVED	1	PubMed
40624944	DERIVED	1	PubMed
32216457	DERIVED	1	PubMed
29396788	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100431

GET https://conductscience.org/api/diseases/v1/MONDO_0100431/targets?page=2

API reference For AI assistants